Related Experiment Videos
In vitro inactivation of aminoglycosides by apalcillin
Antimicrobial Agents and Chemotherapy
|February 1, 1986
Abstract:
Apalcillin, at concentrations of 75, 150, 300, and 600 micrograms/ml, was combined in vitro with amikacin, gentamicin, netilmicin, or tobramycin. Incubation at 37 degrees C resulted in an apalcillin concentration-dependent and time-dependent decrease of aminoglycoside activity of up to 60%. Amikacin was the most stable and tobramycin was the least stable aminoglycoside under the conditions tested.
Insights
Apalcillin reduces aminoglycoside antibiotic activity in vitro, with effects increasing with apalcillin concentration. Amikacin showed the most stability, while tobramycin was least stable.
Area of Science:
- Pharmacology
- Microbiology
- Drug Interactions
Background:
- Aminoglycosides are critical antibiotics for treating severe bacterial infections.
- Understanding potential interactions between different antibiotic classes is crucial for effective therapy.
Purpose of the Study:
- To investigate the in vitro interaction between apalcillin and several key aminoglycoside antibiotics.
- To quantify the impact of apalcillin on aminoglycoside activity.
Main Methods:
- Apalcillin was combined with amikacin, gentamicin, netilmicin, and tobramycin at varying concentrations (75–600 µg/ml).
- Incubation was performed at 37°C to simulate physiological conditions.
- Aminoglycoside activity was assessed following incubation.
Main Results:
- Apalcillin demonstrated a concentration-dependent and time-dependent decrease in aminoglycoside activity, up to 60%.
- Amikacin exhibited the highest stability when combined with apalcillin.
- Tobramycin showed the least stability among the tested aminoglycosides.
Conclusions:
- Apalcillin can significantly reduce the in vitro activity of common aminoglycosides.
- The degree of interaction varies among aminoglycosides, with amikacin being the most resistant.
- These findings highlight the importance of considering potential antagonistic effects when co-administering apalcillin and aminoglycosides.